GYRE Gyre Therapeutics Inc
Price (delayed)
$13.73
Market cap
$1.28B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.38
Enterprise value
$1.27B
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic
Highlights
GYRE's EPS has surged by 98% year-on-year and by 2.6% since the previous quarter
The company's equity rose by 7% QoQ
The net income has plunged by 160% YoY but it has grown by 2.1% from the previous quarter
GYRE's quick ratio is down by 23% year-on-year but it is up by 6% since the previous quarter
Key stats
What are the main financial stats of GYRE
Market
Valuations
Earnings
Shares outstanding
93.42M
Market cap
$1.28B
Enterprise value
$1.27B
Price to earnings (P/E)
N/A
Price to book (P/B)
19.45
Price to sales (P/S)
7.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.65
Revenue
$165.85M
EBIT
-$67.12M
EBITDA
-$64.75M
Free cash flow
$22.7M
Per share
Balance sheet
Liquidity
EPS
-$0.38
Free cash flow per share
$0.27
Book value per share
$0.71
Revenue per share
$1.94
TBVPS
$1.4
Total assets
$120.93M
Total liabilities
$27.58M
Debt
$1.96M
Equity
$60.35M
Working capital
$37.95M
Debt to equity
0.03
Current ratio
3.44
Quick ratio
3.2
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
-39%
Gross margin
96.2%
Net margin
-48%
Operating margin
-32.3%
Return on assets
-86.3%
Return on equity
-304.4%
Return on invested capital
-117.5%
Return on capital employed
-63.7%
Return on sales
-40.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GYRE stock price
How has the Gyre Therapeutics stock price performed over time
Intraday
-0.44%
1 week
16.16%
1 month
28.68%
1 year
89.12%
YTD
-46.56%
QTD
15.09%
Financial performance
How have Gyre Therapeutics's revenue and profit performed over time
Revenue
$165.85M
Gross profit
$159.46M
Operating income
-$53.53M
Net income
-$79.66M
Gross margin
96.2%
Net margin
-48%
The net income has plunged by 160% YoY but it has grown by 2.1% from the previous quarter
Gyre Therapeutics's net margin has shrunk by 144% YoY
GYRE's gross profit is up by 7% year-on-year but it is down by 2.3% since the previous quarter
GYRE's revenue is up by 6% year-on-year but it is down by 2.4% since the previous quarter
Growth
What is Gyre Therapeutics's growth rate over time
Valuation
What is Gyre Therapeutics stock price valuation
P/E
N/A
P/B
19.45
P/S
7.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.65
GYRE's EPS has surged by 98% year-on-year and by 2.6% since the previous quarter
The company's equity rose by 7% QoQ
The stock's price to sales (P/S) is 13% less than its 5-year quarterly average of 8.2 and 3.9% less than its last 4 quarters average of 7.4
GYRE's revenue is up by 6% year-on-year but it is down by 2.4% since the previous quarter
Efficiency
How efficient is Gyre Therapeutics business performance
GYRE's return on sales has dropped by 193% year-on-year
The ROE has soared by 85% since the previous quarter and by 56% year-on-year
GYRE's ROIC is up by 39% from the previous quarter and by 19% YoY
Gyre Therapeutics's ROA has increased by 31% from the previous quarter but it has decreased by 3.2% YoY
Dividends
What is GYRE's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Gyre Therapeutics financials performed over time
GYRE's current ratio is up by 26% year-on-year and by 7% since the previous quarter
GYRE's quick ratio is down by 23% year-on-year but it is up by 6% since the previous quarter
Gyre Therapeutics's debt is 97% lower than its equity
The company's equity rose by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.